Navigating a Pathway to Improve Treatment of Psoriasis

Released On
September 30, 2019

Expires On
September 30, 2020

Media Type
Internet

Completion Time
60 minutes

Specialty
Dermatology

Topic(s)
Psoriasis

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Annenberg Center for Health Sciences.


Supported by in part by an educational grant from Lilly. This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

The target learning audience is a national audience of dermatologists, dermatology physician assistants, nurse practitioners, and other clinicians who treat patients with moderate-to-severe psoriasis.

Program Overview

In this subway-themed activity you can choose different subway lines for the education that is the most relevant to you. Steven Feldman, MD, PhD, discusses some of the recent developments in the management of psoriasis, with a focus on the biologic therapies. He summarizes key points from the American Academy of Dermatology and National Psoriasis Foundation consensus guidelines for managing comorbid conditions, treatment targets, and the clinical application of biologics. Dr. Feldman adds his perspective on how to address patient concerns about the safety of biologic treatments and the increased risk of comorbidities patients with psoriasis may face.

Content Areas:

  • Comorbidities in patients with psoriasis
  • Biologic treatments for psoriasis
  • Safety of biologic treatments for psoriasis
  • TNFα inhibitors
  • IL-17 inhibitors
  • IL-23 inhibitors

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the most common adverse events associated with biologic treatments for psoriasis
  • Select biologic treatments based on patient characteristics and comorbid conditions
  • Apply the results of clinical trials, expert recommendations, and consensus guidelines to develop treatment plans

Faculty

Steven R. Feldman, MD, PhD

Professor of Dermatology, Pathology and Public Health Sciences
Department of Dermatology
Wake Forest School of Medicine
Winston-Salem, North Carolina

Physician Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physician Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Steven R. Feldman, MD, PhD

  • Research Support: AbbVie, Celgene, Galderma Laboratories, LP, Janssen, Lilly, Novartis Pharmaceuticals Corporation, Pfizer Inc, Regeneron, Sanofi, Taro
  • Consultant: AbbVie, Advance Medical, Alvotech, Caremark, Celgene, Galderma Laboratories, LP, Gerson Lehrman Group, Guidepoint Global, Janssen, Kikaku, Leo Pharma Inc, Lilly, Merck & Co, Inc, Mylan, Novartis Pharmaceuticals Corporation, Pfizer Inc, Regeneron, Sanofi, Sienna, Sun Pharma, Suncare Research, Ortho Dermatologics, Xenoport
  • Speakers Bureau: AbbVie, Celgene, Janssen, Leo Pharma Inc, Lilly, Novartis Pharmaceuticals Corporation, Ortho Dermatologics, Pfizer Inc, Regeneron, Sanofi, Sun Pharma, Taro,
  • Significant Shareholder: Causa Technologies, Medical Quality Enhancement Corporation
  • Royalties: Informa, UpToDate, Xlibris
  • Other: Founder and Chief Technology Officer of Causa Technologies

The faculty for this activity has disclosed that there will be discussion about the use of products for non-FDA approved indications.

Additional content planners

Chris Fisher, MSc (medical writer) has no significant relationship to disclose.

Coy Flowers, MD (peer reviewer) has no significant relationship to disclose

Annenberg Center for Health Sciences

All staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

Disclosure Statement

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Method of Participation

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive credit for participation, participants must complete the post-test (achieving a passing grade) and program evaluation. Certificates can be printed immediately.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclaimer

It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.